Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 701–800 of 15,747
Hyams, C., Marlow, R., Maseko, Z., King, J., Ward, L., Fox, K., Heath, R., Tuner, A., Friedrich, Z., Morrison, L., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00330-3 · Cited by 131
Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines
Blakney, A. K., McKay, P. F., Hu, K., Samnuan, K., Jain, N., Brown, A., Thomas, A. M., Rogers, P., Polra, K., Sallah, H., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.029 · Cited by 142
“LNP are the most clinically progressed formulation technology for both saRNA and mRNA, with the recent Emergency Use Authorization of the Pfizer/BioNTech [12] and Moderna [13] COVID-19 vaccines, which are both LNP formulations.”
BackgroundSokal, A., Spaeth, G. B., Fernández, I., Broketa, M., Azzaoui, I., Selle, A. D. L., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.09.011 · Cited by 140
Antibody and B cell responses to SARS-CoV-2 infection and vaccination
Röltgen, K., & Boyd, S. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.009 · Cited by 158
Britton, A., Jacobs Slifka, K. M., Edens, C., Nanduri, S. A., Bart, S. M., Shang, N., Harizaj, A., Armstrong, J., Xu, K., Ehrlich, H. Y., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7011e3 · Cited by 135
Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines
Abu-Hammad, O. A., Alduraidi, H., Abu‐Hammad, S., Alnazzawi, A. A., Babkair, H. A., Abu-Hammad, A., Nourwali, I., Qasem, F., & Dar-Odeh, N. S. (2021) · Vaccines · doi:10.3390/vaccines9060577 · Cited by 142
“Vaccine effectiveness in preventing COVID-19 was reported to be 95% for PB [24] and 70.”
BackgroundControlling the pandemic during the SARS-CoV-2 vaccination rollout
Viana, J., van Dorp, C. H., Nunes, A., Gomes, M. C., van Boven, M., Kretzschmar, M., Veldhoen, M., & Rozhnova, G. (2021) · Nature Communications · doi:10.1038/s41467-021-23938-8 · Cited by 150
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
(2022) · Journal of Liver Cancer · doi:10.17998/jlc.2022.11.07 · Cited by 153
RNA‐based medicine: from molecular mechanisms to therapy
Sparmann, A., & Vogel, J. (2023) · The EMBO Journal · doi:10.15252/embj.2023114760 · Cited by 157
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
Malard, F., Gaugler, B., Gozlan, J., Bouquet, L., Fofana, D., Siblany, L., Eshagh, D., Adotévi, O., Laheurte, C., Ricard, L., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00534-z · Cited by 149
Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
Tada, T., Zhou, H., Samanovic, M. I., Dcosta, B. M., Cornelius, A., Herati, R. S., Mulligan, M. J., & Landau, N. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.797589 · Cited by 135
“The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest a potential benefit by second immunization following Ad26.”
BackgroundInfluentialKapłonek, P., Cizmeci, D., Fischinger, S., Collier, A.-R. Y., Suscovich, T. J., Linde, C., Broge, T. A., Mann, C. J., Amanat, F., Dayal, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm2311 · Cited by 139
“Robust protection was observed in phase 3 trials of Pfizer/BioNTech BNT162b2 (4) and Moderna mRNA-1273 (21), with 94.”
InfluentialHigdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S. A., Baidya, A., Nande, A. A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac138 · Cited by 133
Woldemeskel, B. A., Karaba, A. H., Garliss, C. C., Beck, E. J., Wang, K., Laeyendecker, O. B., Cox, A. L., & Blankson, J. N. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab648 · Cited by 135
Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., Betts, B., Buzzanco, A. S., Gonzalez, J., Chinthrajah, R. S., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.25524 · Cited by 132
In vivo CAR engineering for immunotherapy
Li, Y.-R., Zhu, Y., Halladay, T., & Yang, L. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01174-1 · Cited by 172
“Among the various approaches to in vivo CAR engineering, LNP–mRNA-based CARs have a strong chance of reaching the clinic first, leveraging the manufacturing and regulatory advancements established during the COVID-19 pandemic 35,37,103,126 .”
Ruether, D. F., Schaub, G., Duengelhoef, P. M., Haag, F., Brehm, T. T., Fathi, A., Wehmeyer, M. H., Jahnke-Triankowski, J., Mayer, L., Hoffmann, A., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.003 · Cited by 137
Madelon, N., Lauper, K., Bréville, G., Royo, I. S., Goldstein, R., Andrey, D. O., Grifoni, A., Sette, A., Kaiser, L., Siegrist, C., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab954 · Cited by 150
“Additionally, it has been recently shown that robust and functional CD8+ T cell responses are elicited only one week after the BNT162b2 prime vaccination when neutralizing antibodies are weakly detected [29] and at a time when protective effect of COVID-19 mRNA vaccines can be observed [30, 31].”
BackgroundUveitis and Other Ocular Complications Following COVID-19 Vaccination
Bolletta, E., Iannetta, D., Mastrofilippo, V., Simone, L. D., Gozzi, F., Croci, S., Bonacini, M., Belloni, L., Zerbini, A., Adani, C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245960 · Cited by 135
“Pfizer-BioNTech [5]; mRNA-1273, ModernaTX [6]), and the protein subunit vaccine (NVXCoV2373, Novavax [7]).”
BackgroundNovel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines
Aida, V., Pliasas, V. C., Neasham, P. J., North, J. F., McWhorter, K. L., Glover, S. R., & Kyriakis, C. S. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.654289 · Cited by 160
“In late 2020, the United Kingdom became the first sovereign country to approve Tozinameran INN, a messenger RNA vaccine (co-produced by Pfizer and BioNTech) indicated for the prevention of SARS-CoV-2 infection, the agent responsible for the COVID-19 pandemic (233).”
BackgroundSynthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics
Tan, X., Letendre, J. H., Collins, J. J., & Wong, W. W. (2021) · Cell · doi:10.1016/j.cell.2021.01.017 · Cited by 131
Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis
Danwang, C., Noubiap, J. J., Robert, A. R., & Yombi, J. C. (2022) · AIDS Research and Therapy · doi:10.1186/s12981-021-00427-y · Cited by 159
Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2
Psichοgiou, M., Samarkos, M., Mikos, N., & Hatzakis, A. E. (2021) · Vaccines · doi:10.3390/vaccines9060572 · Cited by 141
“Moreover, the study includes 2 months of follow-up in half of the participants [1].”
BackgroundInfluentialExploiting viral sensing mediated by Toll-like receptors to design innovative vaccines
Sartorius, R., Trovato, M., Manco, R., D’Apice, L., & De Berardinis, P. (2021) · npj Vaccines · doi:10.1038/s41541-021-00391-8 · Cited by 131
Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
Lee, J., Woodruff, M. C., Kim, E. H., & Nam, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00999-x · Cited by 149
Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle?
Orvieto, R., Noach‐Hirsh, M., Segev-Zahav, A., Haas, J., Nahum, R., & Aizer, A. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00757-6 · Cited by 167
“SARS-CoV-2 infection a week following the second dose, with a favorable safety profile in a 2-month median follow up time [7].”
InfluentialHydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
Patel, S. K., Billingsley, M. M., Frazee, C. P., Han, X., Swingle, K. L., Qin, J., Alameh, M., Wang, K., Weissman, D., & Mitchell, M. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.020 · Cited by 147
“FDA approval of Alnylam's Onpattro [33] as well as emergency use authorization of LNPs for the Moderna and Pfizer/BioNTech COVID-19 mRNA vaccines [14,16].”
BackgroundPal, R., Bhadada, S. K., & Misra, A. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.02.026 · Cited by 145
COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials
Yan, Z., Yang, M., & Lai, C. (2021) · Pharmaceuticals · doi:10.3390/ph14050406 · Cited by 144
“BNT162b2 [7,8] 1–3 43,448 volunteers aged 16 or older in total: (1:1 ratio) 21,720 received vaccines 21,728 received placebo 2 injections of 30 μg doses for phase 3, 21 days apart Lipid nanoparticle nucleoside-modified mRNA vaccine, encoding the spike glycoprotein of SARS-CoV-2 Similar dose-dependent response as BNT16…”
BackgroundMethodAlexander, J. L., Moran, G. W., Gaya, D. R., Raine, T., Hart, A. L., Kennedy, N. A., Lindsay, J. O., MacDonald, J. C., Segal, J. P., Sebastian, S., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00024-8 · Cited by 142
Bensouna, I., Caudwell, V., Kubab, S., Acquaviva, S., Pardon, A., Vittoz, N., Bozman, D.-F., Hanafi, L., Faucon, A., & Housset, P. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.08.005 · Cited by 132
“A 2-dose regimen of BNT162b2 vaccine is 95% effective in preventing coronavirus disease 2019 (COVID-19) in the general population.(6)”
Aptamer-Based Targeted Delivery of Functional Nucleic Acids
Xie, S., Sun, W., Fu, T., Liu, X., Chen, P., Qiu, L., Qu, F., & Tan, W. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c00841 · Cited by 137
Kuter, B. J., Browne, S., Momplaisir, F. M., Feemster, K. A., Shen, A. K., Green-McKenzie, J., Faig, W. G., & Offit, P. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.02.029 · Cited by 145
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
Walgrave, H., Zhou, L., De Strooper, B., & Salta, E. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00496-7 · Cited by 131
“Most notably, over the last year the world has witnessed the first mRNA vaccines to enter the clinic, developed my Moderna and Pfizer against the SARS-CoV-2 virus [232, 233].”
BackgroundGorman, M. J., Patel, N., Guebre-Xabier, M., Zhu, A. L., Atyeo, C., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100405 · Cited by 129
“Preliminary retrospective analysis of the first dose of the Pfizer/BNT162b2 before boosting suggested approximately a 52% protection from severe infection, whereas more-recent studies have suggested a single dose is 85% effective at preventing death.(5,46,47) In addition, recent results from Johnson and Johnson’s sing…”
Liu, Y., Qin, C., Rao, Y., Ngo, C., Feng, J. J., Zhao, J., Zhang, S., Wang, T.-Y., Carriere, J., Savas, A. C., et al. (2021) · mBio · doi:10.1128/mbio.02335-21 · Cited by 129
(2021) · doi:10.1101/2021.04.06.21254882 · Cited by 373
Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics
Ewert, K. K., Scodeller, P., Simón‐Gracia, L., Steffes, V. M., Wonder, E. A., Teesalu, T., & Safinya, C. R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091365 · Cited by 132
Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines
Rijkers, G. T., Weterings, N., Obregón‐Henao, A., Dutt, T., Dutt, T. S., van Overveld, F. J., & Henao-Tamayo, M. I. (2021) · Vaccines · doi:10.3390/vaccines9080848 · Cited by 152
Tram, K. H., Saeed, S., Bradley, C., Fox, B., Eshun‐Wilson, I., Mody, A., & Geng, E. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab633 · Cited by 152
Rhym, L. H., Manan, R. S., Koller, A. A., Stephanie, G., & Anderson, D. G. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01030-4 · Cited by 145
COVID-19 mRNA vaccination leading to CNS inflammation: a case series
Khayat-Khoei, M., Bhattacharyya, S., Katz, J., Harrison, D. S., Tauhid, S., Bruso, P., Houtchens, M. K., Edwards, K. R., & Bakshi, R. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10780-7 · Cited by 132
Escaping the endosome: assessing cellular trafficking mechanisms of non-viral vehicles
Xu, E., Saltzman, W. M., & Piotrowski-Daspit, A. S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.038 · Cited by 144
Klimek, L., Novak, N., Cabanillas, B., Jutel, M., Bousquet, J. J., & Akdiş, C. A. (2021) · Allergy · doi:10.1111/all.14794 · Cited by 136
The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland
Rzymski, P., Zeyland, J., Poniedziałek, B., Małecka, I., & Wysocki, J. (2021) · Vaccines · doi:10.3390/vaccines9040382 · Cited by 142
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva
Ketas, T. J., Chaturbhuj, D. N., Portillo, V. M. C., Francomano, E., Golden, E. B., Chandrasekhar, S., Debnath, G., Diaz-Tapia, R., Yasmeen, A., Kramer, K. D., et al. (2021) · Pathogens and Immunity · doi:10.20411/pai.v6i1.441 · Cited by 139
“A report on SARS-CoV-2 infection in rhesus macaques shows that virus can still replicate in nasal turbinates even when it is suppressed in the lungs by passively transferred NAbs [28].”
InfluentialBae, S., Lee, Y. W., Lim, S. Y., Lee, J., Lim, J. S., Lee, S., Park, S., Kim, S.-K., Lim, Y., Kim, E. O., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e115 · Cited by 141
Gupta, S., Cantor, J., Simon, K. I., Bento, A. I., Wing, C., & Whaley, C. M. (2021) · Health Affairs · doi:10.1377/hlthaff.2021.00619 · Cited by 128
The landscape of T cell antigens for cancer immunotherapy
Peri, A., Salomon, N., Wolf, Y., Kreiter, S., Diken, M., & Samuels, Y. (2023) · Nature Cancer · doi:10.1038/s43018-023-00588-x · Cited by 147
Physiological Barriers and Strategies of Lipid‐Based Nanoparticles for Nucleic Acid Drug Delivery
Hu, M., Li, X., You, Z., Cai, R., & Chen, C. (2023) · Advanced Materials · doi:10.1002/adma.202303266 · Cited by 167
Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program
Brannock, D., Chew, R., Preiss, A., Hadley, E., Redfield, S., McMurry, J. A., Leese, P., Girvin, A. T., Crosskey, M., Zhou, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38388-7 · Cited by 148
Christensen, P. A., Olsen, R. J., Long, S. W., Subedi, S., Davis, J. J., Hodjat, P., Walley, D. R., Kinskey, J. C., Saavedra, M. O., Pruitt, L., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.10.019 · Cited by 137
Nanovaccine: an emerging strategy
Das, A., & Ali, N. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1984890 · Cited by 137
“1% and 95% protection against COVID-19 in adults, respectively, without any serious adverse effects [166,167].”
BackgroundPlacenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia
Swingle, K. L., Hamilton, A. G., Safford, H. C., Geisler, H. C., Thatte, A. S., Palanki, R., Murray, A. M., Han, E. L., Mukalel, A. J., Han, X., et al. (2025) · Nature · doi:10.1038/s41586-024-08291-2 · Cited by 129
“…a non-viral platform for nucleic acid delivery, with the Food and Drug Administration approval of the Onpattro siRNA therapeutic for hereditary transthyretin-mediated amyloidosis (hATTR) in 2018 and the Pfizer/BioNTech and Moderna COVID-19 messenger RNA (mRNA) vaccines a few years later 3,17,18 .”
Jara, L. J., Lastra, O. L. V., Mahroum, N., Pineda, C., & Shoenfeld, Y. (2022) · Clinical Rheumatology · doi:10.1007/s10067-022-06149-4 · Cited by 154
mRNA nanomedicine: Design and recent applications
Kubiatowicz, L. J., Mohapatra, A., Krishnan, N., Fang, R. H., & Zhang, L. (2022) · Exploration · doi:10.1002/exp.20210217 · Cited by 138
Chen, J., Wang, P., Yuan, L., Zhang, L., Zhang, L., Zhao, H. J., Chen, C., Chen, Y., Han, J., Jia, J., et al. (2022) · 中国科学通报:英文版 · doi:10.1016/j.scib.2022.05.018 · Cited by 133
The roles of polymers in mRNA delivery
Huang, P., Deng, H., Zhou, Y., & Chen, X. S. (2022) · Matter · doi:10.1016/j.matt.2022.03.006 · Cited by 134
Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies
Wei, P.-S., Thota, N., John, G., Chang, E., Lee, S., Wang, Y., Ma, Z., Tsai, Y.-H., & Mei, K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.030 · Cited by 149
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Milne, G., Hames, T., Scotton, C. J., Gent, N., Johnsen, A., Anderson, R. M., & Ward, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00407-0 · Cited by 142
Vaccine nationalism and the dynamics and control of SARS-CoV-2
Wagner, C. E., Saad-Roy, C. M., Morris, S. E., Baker, R. E., Mina, M. J., Farrar, J., Holmes, E. C., Pybus, O. G., Graham, A. L., Emanuel, E., et al. (2021) · Science · doi:10.1126/science.abj7364 · Cited by 133
Gilboa, M., Regev-Yochay, G., Mandelboim, M., Indenbaum, V., Asraf, K., Fluss, R., Amit, S., Mendelson, E., Doolman, R., Afek, A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31778 · Cited by 128
Post-Acute COVID-19 Syndrome and the cardiovascular system: What is known?
Dixit, N. M., Churchill, A., Nsair, A., & Hsu, J. J. (2021) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2021.100025 · Cited by 153
“With the emerging success of the COVID-19 vaccines, the burden of acute COVID-19 will wane, but we will likely be left with a significant number of patients with persistent symptoms even months after COVID-19 infection [80,81].”
van der Ley, P., Zariri, A., van Riet, E., Oosterhoff, D., & Kruiswijk, C. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.781280 · Cited by 140
“Several of the first vaccines developed, like the mRNA vaccines mRNA-1273 (2) and BNT162b2 (26), use S-2P in their vaccine designs.”
BackgroundKreps, S. E., Dasgupta, N., Brownstein, J. S., Hswen, Y., & Kriner, D. L. (2021) · npj Vaccines · doi:10.1038/s41541-021-00335-2 · Cited by 130
Langel, S. N., Johnson, S., Martinez, C. I., Tedjakusuma, S. N., Peinovich, N., Dora, E. G., Kuehl, P. J., Irshad, H., Barrett, E. G., Werts, A. D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn6868 · Cited by 131
Atyeo, C. G., DeRiso, E. A., Wiggins, C. D., Bordt, E. A., Guzman, R. M. D., Shook, L. L., Yonker, L. M., Fasano, A., Akinwunmi, B. O., Lauffenburger, D. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi8631 · Cited by 128
“Both EUA-approved COVID-19 mRNA vaccines have been shown to be safe and highly immunogenic in non-pregnant populations (14, 15), and emerging data suggest that the vaccines are immunogenic and similarly reactogenic in pregnant and lactating women (18).”
BackgroundNeurological autoimmune diseases following vaccinations against SARS‐CoV‐2: a case series
Kaulen, L. D., Doubrovinskaia, S., Mooshage, C. M., Jordan, B., Purrucker, J. C., Haubner, C., Seliger, C., Lorenz, H., Nagel, S., Wildemann, B., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.15147 · Cited by 133
Luo, C., Yang, Y., Liu, Y., Zheng, D., Shao, L., Jin, J., & He, Q. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.06.020 · Cited by 149
“Last but not least, it is encouraging that COVID-19 vaccine have proven 95% efficacy in the prevention of COVID-19 infection in a multinational, large sample size randomized controlled trial.(11) Accordingly, the principal objective of this meta-analysis was to investigate the intention to vaccinate against COVID-19 a…”
Wang, Y., & Liu, Y. (2021) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2021.101673 · Cited by 139
“Both vaccines have been effective in preventing infection with COVID-19 and conferring promising protection against variants of the virus (Polack et al., 2020; Abu-Raddad et al., 2021; Baden et al., 2021; Wu et al., 2021; Lopez Bernal et al., 2021).”
The immunostimulatory nature of mRNA lipid nanoparticles
Sharma, P., Hoorn, D., Aitha, A., Breier, D., & Peer, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115175 · Cited by 143
Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance
Shaqra, A. M., Zvornicanin, S. N., Huang, Q. Y. J., Lockbaum, G. J., Knapp, M., Tandeske, L., Bakan, D. T., Flynn, J., Bolon, D. N. A., Moquin, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31210-w · Cited by 121
Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2022) · Nature · doi:10.1038/s41586-021-04231-6 · Cited by 141
Cohen, D., Krauthammer, S. H., Wolf, I., & Even‐Sapir, E. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05314-2 · Cited by 126
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
Peled, Y., Ram, E., Lavee, J., Sternik, L., Segev, A., Wieder-Finesod, A., Mandelboim, M., Indenbaum, V., Levy, I., Raanani, E., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.003 · Cited by 126
“4% reported at least one systemic reaction.(1) In the nontransplant population, the BNT162b2 vaccine elicits antibody responses against the RBD, and plasma binding and neutralizing activity of the vaccine against SARS-CoV-2 has been demonstrated.”
Circular RNA: A promising new star of vaccine
Xie, J., Ye, F., Deng, X., Tang, Y., Liang, J., Huang, X., Sun, Y., Tang, H., Lei, J., Zheng, S., et al. (2023) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0122 · Cited by 130
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
Hwang, J. K., Zhang, T., Wang, A. Z., & Li, Z. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01046-w · Cited by 132
Wang, L., Wang, Q., Davis, P. B., Volkow, N. D., & Xu, R. (2022) · World Psychiatry · doi:10.1002/wps.20921 · Cited by 126
Acuña‐Zegarra, M. A., Díaz‐Infante, S., Baca-Carrasco, D., & Olmos‐Liceaga, D. (2021) · Mathematical Biosciences · doi:10.1016/j.mbs.2021.108614 · Cited by 137
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
Bird, S. A., Panopoulou, A., Shea, R. L., Tsui, M., Saso, R. M., Sud, A., West, S., Smith, K., Barwood, J., Kaczmarek, E., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00110-1 · Cited by 129
Farshbafnadi, M., Zonouzi, S. K., Sabahi, M., Dolatshahi, M., & Aarabi, M. H. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111507 · Cited by 156
Critical Appraisal of Large Vitamin D Randomized Controlled Trials
Pilz, S., Trummer, C., Theiler‐Schwetz, V., Grübler, M. R., Verheyen, N., Odler, B., Karras, S. Ν., Zittermann, A., & März, W. (2022) · Nutrients · doi:10.3390/nu14020303 · Cited by 141
SARS-CoV-2 vaccines: Lights and shadows
Angeli, F., Spanevello, A., Reboldi, G., Visca, D., & Verdecchia, P. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.04.019 · Cited by 134
“In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, subjects 16 years of age or older are randomized in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate [11].”
Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study
Vokó, Z., Kiss, Z., Surján, G., Surján, O., Barcza, Z., Pályi, B., Formanek-Balku, E., Molnár, G. A., Herczeg, R., Gyenesei, A., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.011 · Cited by 143
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Hassan, A. O., Shrihari, S., Gorman, M. J., Ying, B., Yuan, D., Raju, S., Chen, R. E., Dmitriev, I. P., Kashentseva, E. A., Adams, L. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109452 · Cited by 138
Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database
Kaur, R., Dutta, S., Charan, J., Bhardwaj, P., Tandon, A., Yadav, D., Islam, S., & Haque, M. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s324349 · Cited by 125
Haas, E. J., McLaughlin, J. M., Khan, F. L., Angulo, F. J., Anis, E., Lipsitch, M., Singer, S. R., Mircus, G., Brooks, N., Smaja, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00566-1 · Cited by 144
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality
Nakanishi, T., Pigazzini, S., Degenhardt, F., Cordioli, M., Butler‐Laporte, G., Maya‐Miles, D., Jiménez, B. N., Bouysran, Y., Niemi, M., Palom, A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152386 · Cited by 130
“Although vaccination development for SARS-CoV-2 has successfully reduced COVID-19 disease burden in many countries (26, 27), SARS-CoV-2 will likely become endemic in the human population, and it is still not known how long vaccine protection will last.”
BackgroundClinical delivery of circular RNA: Lessons learned from RNA drug development
Young, T. L., Wang, K. C., Varley, A., & Li, B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114826 · Cited by 133
Huang, X., Chuang, L. I. U., Kong, N., Xiao, Y., Yurdagul, A., Tabas, I. A., & Tao, W. (2022) · Nature Protocols · doi:10.1038/s41596-021-00665-4 · Cited by 127
Katikireddi, S. V., Cerqueira-Silva, T., Vasileiou, E., Robertson, C., Amele, S., Pan, J., Taylor, B., Boaventura, V., Werneck, G. L., Flores-Ortiz, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02754-9 · Cited by 124
“Randomised trials for ChAdOx1 nCoV-19 have shown short-term effective protection against severe COVID-19 disease; 1,30 however, research on potential vaccine waning has mainly focused on BNT162b2.”
Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients
Yanay, N. B., Freiman, S., Shapira, M., Wishahi, S., Hamze, M., Elhaj, M., Zaher, M., & Armaly, Z. (2021) · Kidney International · doi:10.1016/j.kint.2021.04.006 · Cited by 131
“1496 stages of the chronic kidney disease.(6) We investigated dialysis patients and a control group who had completed 2 doses of vaccination with the mRNA BNT162b2 vaccine for anti–spike protein antibody response (LIAISON SARS-CoV-2 S1/S2 IgG; DiaSorin) and observed them for up to 10 weeks (for detailed methods, see t…”
Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C. L., Ma, T., Leung, M. T. Y., Tsao, S. S. L., Kan, E. Y. L., Ng, W. K. C., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab989 · Cited by 128
“The Comirnaty is a messenger RNA (mRNA) vaccine that is highly effective in preventing hospitalizations and deaths due to COVID-19 [6].”
BackgroundBlauenfeldt, R. A., Kristensen, S. R., Ernstsen, S. L., Hilt, C., Simonsen, C. Z., & Hvas, A. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15347 · Cited by 133
Dhakal, B., Abedin, S. M., Fenske, T. S., Chhabra, S., Ledeboer, N. A., Hari, P., & Hamadani, M. (2021) · Blood · doi:10.1182/blood.2021012769 · Cited by 126
SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review
Fathizadeh, H., Afshar, S., Masoudi, M. R., Gholizadeh, P., Asgharzadeh, M., Ganbarov, K., Köse, Ş., Yousefi, M., & Kafil, H. S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.08.076 · Cited by 139
“Pfizer and BioNTech have also developed several RNA-based vaccines that have been successful in clinical trials and are now being used in many countries [49,92].”
Emerging vaccine nanotechnology: From defense against infection to sniping cancer
Feng, C., Li, Y., Ferdows, B. E., Patel, D. N., Ouyang, J., Tang, Z., Kong, N., Chen, E., & Tao, W. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.021 · Cited by 140
BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees
Alghamdi, A. N., Alotaibi, M. I., Alqahtani, A. S., Aboud, D. A., & Abdel-Moneim, A. S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.760047 · Cited by 134
“This finding agrees with the data of phase 2/3 clincal trial that reported 88% pain at the site of injection following vaccination with ChAdOx1 (25), in individuals 18–55 of age and it reached >80% in individuals (≥16 years old) vaccinated with BNT162b2 (23).”
ResultImmunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Geers, D., Schmitz, K. S., Garcia Garrido, H. M., Koopmans, M. P. G., Dalm, V. A. S. H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116747 · Cited by 124
Hewavisenti, R., Arena, J., Ahlenstiel, C., & Sasson, S. C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1112513 · Cited by 165
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.